Russell Horn
Family Medicine · Valley Center, KSNPI 1528062148
Payments from drug & device makers
Across 196 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$519
- Novo Nordisk$518
- AbbVie$258
- Lilly USA, LLC$226
- Amarin Pharma, Inc.$200
- Johnson & Johnson$168
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,096100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $519 |
| Novo Nordisk | 33 | $518 |
| AbbVie(2 entities) | 18 | $258 |
| Lilly USA, LLC | 17 | $226 |
| Amarin Pharma, Inc. | 11 | $200 |
| Johnson & Johnson | 12 | $168 |
| Abbott | 9 | $166 |
| Pfizer | 9 | $133 |
| Boehringer Ingelheim | 8 | $127 |
| Merck | 7 | $98 |
| E.r. Squibb & Sons, L.L.C. | 3 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Sanofi Pasteur Inc. | 4 | $78 |
| Bayer | 5 | $75 |
| Eisai Inc. | 3 | $58 |
| GSK | 3 | $54 |
| Amgen | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 3 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Apria Healthcare LLC | 1 | $15 |
How this compares
$3,096 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $8,896 |
| Labetalol Hcl | 16 | $625 |
| Gabapentin | 17 | $355 |
| Amlodipine Besylate | 70 | $352 |
| Levothyroxine Sodium | 42 | $309 |
| Omeprazole | 38 | $278 |
| Potassium Chloride | 17 | $251 |
| Atorvastatin Calcium | 47 | $210 |
| Tamsulosin Hcl | 19 | $195 |
| Famotidine | 15 | $192 |
| Losartan Potassium | 41 | $157 |
| Hydrochlorothiazide | 14 | $133 |
| Furosemide | 18 | $94 |
| Montelukast Sodium | 11 | $90 |
| Simvastatin | 20 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $133 | $8,89617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Valley Center
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.